Molecular Oncology
Volume 3, Issue 5 , Pages 402-408 , December 2009

The role of protein synthesis in cell cycling and cancer

  • Shai White-Gilbertson

      Affiliations

    • Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USA
    • ,
  • David T. Kurtz

      Affiliations

    • Department of Pharmacology, Medical University of South Carolina, Charleston, SC 29425, USA
    • ,
  • Christina Voelkel-Johnson

      Affiliations

    • Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC 29425, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 843 792 3125; fax: +1 843 792 2464.

Received 22 March 2009 ,Revised 4 May 2009 ,Accepted 25 May 2009.

References 

  1. Alaiya AA, Franzen B, Fujioka K, Moberger B, Schedvins K, Silfversvard C, et al. Phenotypic analysis of ovarian carcinoma: Polypeptide expression in benign, borderline and malignant tumors. Int. J. Cancer. 1997;73:678–683
  2. Altieri DC. New wirings in the survivin networks. Oncogene. 2008;27:6276–6284
  3. Arora S, Yang JM, Hait WN. Identification of the ubiquitin-proteasome pathway in the regulation of the stability of eukaryotic elongation factor-2 kinase. Cancer Res. 2005;65:3806–3810
  4. Arora S, Yang JM, Kinzy TG, Utsumi R, Okamoto T, Kitayama T, et al. Identification and characterization of an inhibitor of eukaryotic elongation factor 2 kinase against human cancer cell lines. Cancer Res. 2003;63:6894–6899
  5. Berridge MJ, Lipp P, Bootman MD. The versatility and universality of calcium signalling. Nat. Rev. Mol. Cell. Biol. 2000;1:11–21
  6. Browne GJ, Finn SG, Proud CG. Stimulation of the amp-activated protein kinase leads to activation of eukaryotic elongation factor 2 kinase and to its phosphorylation at a novel site, serine 398. J. Biol. Chem. 2004;279:12220–12231
  7. Browne GJ, Proud CG. A novel mtor-regulated phosphorylation site in elongation factor 2 kinase modulates the activity of the kinase and its binding to calmodulin. Mol. Cell. Biol. 2004;24:2986–2997
  8. Celis JE, Madsen P, Ryazanov AG. Increased phosphorylation of elongation factor 2 during mitosis in transformed human amnion cells correlates with a decreased rate of protein synthesis. Proc. Natl. Acad. Sci. U.S.A. 1990;87:4231–4235
  9. Cheng EH, Gorelick FS, Czernik AJ, Bagaglio DM, Hait WN. Calmodulin-dependent protein kinases in rat glioblastoma. Cell Growth Differ. 1995;6:615–621
  10. Desdouets C, Matesic G, Molina CA, Foulkes NS, Sassone-Corsi P, Brechot C, et al. Cell cycle regulation of cyclin a gene expression by the cyclic amp-responsive transcription factors creb and crem. Mol. Cell. Biol. 1995;15:3301–3309
  11. Dorovkov MV, Pavur KS, Petrov AN, Ryazanov AG. Regulation of elongation factor-2 kinase by ph. Biochemistry. 2002;41:13444–13450
  12. Duvic M, Talpur R. Optimizing denileukin diftitox (ontak) therapy. Future Oncol. 2008;4:457–469
  13. Fitzgerald D, Pastan I. Pseudomonas exotoxin and recombinant immunotoxins derived from it. Ann. N. Y. Acad. Sci. 1993;685:740–745
  14. Fortugno P, Wall NR, Giodini A, O'Connor DS, Plescia J, Padgett KM, et al. Survivin exists in immunochemically distinct subcellular pools and is involved in spindle microtubule function. J. Cell. Sci. 2002;115:575–585
  15. Gutzkow KB, Lahne HU, Naderi S, Torgersen KM, Skalhegg B, Koketsu M, et al. Cyclic amp inhibits translation of cyclin d3 in t lymphocytes at the level of elongation by inducing eef2-phosphorylation. Cell. Signal. 2003;15:871–881
  16. Huizing MT, Misser VH, Pieters RC, ten Bokkel Huinink WW, Veenhof CH, Vermorken JB, et al. Taxanes: a new class of antitumor agents. Cancer Invest. 1995;13:381–404
  17. Jorgensen R, Merrill AR, Andersen GR. The life and death of translation elongation factor 2. Biochem. Soc. Trans. 2006;34:1–6
  18. Kang KR, Lee SY. Effect of serum and hydrogen peroxide on the ca2+/calmodulin-dependent phosphorylation of eukaryotic elongation factor 2(eef-2) in chinese hamster ovary cells. Exp. Mol. Med. 2001;33:198–204
  19. Kong Q, Lillehei KO. Antioxidant inhibitors for cancer therapy. Med. Hypotheses. 1998;51:405–409
  20. Liu L, Cash TP, Jones RG, Keith B, Thompson CB, Simon MC. Hypoxia-induced energy stress regulates mrna translation and cell growth. Mol. Cell. 2006;21:521–531
  21. Lopez-Lazaro M. The warburg effect: Why and how do cancer cells activate glycolysis in the presence of oxygen?. Anticancer Agents Med. Chem. 2008;8:305–312
  22. Margulis V, Lotan Y, Shariat SF. Survivin: a promising biomarker for detection and prognosis of bladder cancer. World J. Urol. 2008;26:59–65
  23. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin. Cancer Res. 2008;14:5000–5005
  24. Nakamura J, Aoyagi S, Nanchi I, Nakatsuka S, Hirata E, Shibata S, et al. Overexpression of eukaryotic elongation factor eef2 in gastrointestinal cancers and its involvement in g2/m progression in the cell cycle. Int. J. Oncol. 2009;34:1181–1189
  25. Nichols J, Foss F, Kuzel TM, LeMaistre CF, Platanias L, Ratain MJ, et al. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Eur. J. Cancer. 1997;33(Suppl. 1):S34–S36
  26. O'Connor DS, Grossman D, Plescia J, Li F, Zhang H, Villa A, et al. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc. Natl. Acad. Sci. U.S.A. 2000;97:13103–13107
  27. O'Connor DS, Wall NR, Porter AC, Altieri DC. A p34(cdc2) survival checkpoint in cancer. Cancer. Cell. 2002;2:43–54
  28. Okamoto J, Mikami I, Tominaga Y, Kuchenbecker KM, Lin YC, Bravo DT, et al. Inhibition of hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma. J. Thorac. Oncol. 2008;3:1089–1095
  29. Ortiz PA, Kinzy TG. Dominant-negative mutant phenotypes and the regulation of translation elongation factor 2 levels in yeast. Nucleic Acids Res. 2005;33:5740–5748
  30. Parmer TG, Ward MD, Hait WN. Effects of rottlerin, an inhibitor of calmodulin-dependent protein kinase iii, on cellular proliferation, viability, and cell cycle distribution in malignant glioma cells. Cell Growth Differ. 1997;8:327–334
  31. Parmer TG, Ward MD, Yurkow EJ, Vyas VH, Kearney TJ, Hait WN. Activity and regulation by growth factors of calmodulin-dependent protein kinase iii (elongation factor 2-kinase) in human breast cancer. Br. J. Cancer. 1999;79:59–64
  32. Pineiro D, Gonzalez VM, Hernandez-Jimenez M, Salinas M, Martin ME. Translation regulation after taxol treatment in nih3t3 cells involves the elongation factor (eef)2. Exp. Cell. Res. 2007;313:3694–3706
  33. Proud CG. Signalling to translation: how signal transduction pathways control the protein synthetic machinery. Biochem. J. 2007;403:217–234
  34. Roberts EC, Hammond K, Traish AM, Resing KA, Ahn NG. Identification of g2/m targets for the map kinase pathway by functional proteomics. Proteomics. 2006;6:4541–4553
  35. Ryazanov AG, Spirin AS. Phosphorylation of elongation factor 2: a key mechanism regulating gene expression in vertebrates. New Biol. 1990;2:843–850
  36. Saeki K, Yuo A, Takaku F. Cell-cycle-regulated phosphorylation of camp response element-binding protein: identification of novel phosphorylation sites. Biochem. J. 1999;338(1):49–54
  37. Santella L. The role of calcium in the cell cycle: facts and hypotheses. Biochem. Biophys. Res. Commun. 1998;244:317–324
  38. Sivan G, Kedersha N, Elroy-Stein O. Ribosomal slowdown mediates translational arrest during cellular division. Mol. Cell. Biol. 2007;27:6639–6646
  39. Smith EM, Proud CG. Cdc2-cyclin b regulates eef2 kinase activity in a cell cycle- and amino acid-dependent manner. Embo. J. 2008;27:1005–1016
  40. White SJ, Kasman LM, Kelly MM, Lu P, Spruill L, McDermott PJ, et al. Doxorubicin generates a proapoptotic phenotype by phosphorylation of elongation factor 2. Free Radic. Biol. Med. 2007;43:1313–1321
  41. Wu H, Yang JM, Jin S, Zhang H, Hait WN. Elongation factor-2 kinase regulates autophagy in human glioblastoma cells. Cancer. Res. 2006;66:3015–3023
  42. Yang D, Welm A, Bishop JM. Cell division and cell survival in the absence of survivin. Proc. Natl. Acad. Sci. U.S.A. 2004;101:15100–15105
  43. Yang J, Yang JM, Iannone M, Shih WJ, Lin Y, Hait WN. Disruption of the ef-2 kinase/hsp90 protein complex: a possible mechanism to inhibit glioblastoma by geldanamycin. Cancer. Res. 2001;61:4010–4016
  44. Zajac M, Moneo MV, Carnero A, Benitez J, Martinez-Delgado B. Mitotic catastrophe cell death induced by heat shock protein 90 inhibitor in brca1-deficient breast cancer cell lines. Mol. Cancer. Ther. 2008;7:2358–2366
  45. Zhao J, Tenev T, Martins LM, Downward J, Lemoine NR. The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. J. Cell Sci. 2000;113(23):4363–4371

PII: S1574-7891(09)00075-1

doi: 10.1016/j.molonc.2009.05.003

Molecular Oncology
Volume 3, Issue 5 , Pages 402-408 , December 2009

Article Tools

* Image Usage & Resolution